

10/633,402

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: V. Suzanne Klimberg et al.

Examiner: Kevin E. Weddington

Serial No.: 10/633,402

Group Art Unit: 1614

Filed: August 01, 2003

Docket: 781.020US1

Title: IMPROVED TREATMENT OF CANCER WITH GLUTAMINE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

INFORMATION DISCLOSURE STATEMENT

Serial No :10/633,402

Filing Date: August 01, 2003

Title: IMPROVED TREATMENT OF CANCER WITH GLUTAMINE

Page 2

Dkt: 781.020US1

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

The present application is either a U.S. national patent application filed after June 30, 2003 or an international application that entered the national stage under 35 U.S.C. § 371 after June 30, 2003. Thus, Applicant believes that the U.S. Patent & Trademark Office has waived the requirement under 37 C.F.R. 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication. The waiver is provided in a pre-OG notice from the U.S. Patent & Trademark Office entitled "Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003" and dated July 11, 2003. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).


Respectfully submitted,

V. SUZANNE KLIMBERG ET AL.


By their Representatives,


SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6903

Date 29 OCT 04


By 
Warren D. Woessner
Reg. No. 30,440

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 29th day of October, 2004.


Name


Signature

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)



Complete if Known

Application Number	10/633,402
Filing Date	August 1, 2003
First Named Inventor	Klimberg, V. Suzanne
Group Art Unit	1614
Examiner Name	Weddington, Kevin

Sheet 1 of 3

Attorney Docket No: 781.020US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
	US-5,438,075	08/01/1995	Skubitz, , et al.			
	US-5,545,668	08/13/1996	Skubitz, Keith M., et al.	514	561	11/17/1994
	US-5,658,895	08/19/1997	Aoi, S. , et al.	514	58	06/06/1995

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
--------------------	---------------------	------------------	---	-------	----------	----------------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ABCOUWER, S F., et al., "Glutamine deprivation induces the expression of GADD45 and GADD153 primarily by mRNA stabilization", <u>Journal of Biological Chemistry</u> , 274(40), (October 1, 1999),28645-28651	
		ANDERSON, P M., et al., "Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation", <u>Bone Marrow Transplant</u> , 22 (4), (August 1998),339-344	
		ANDERSON, P. , et al., "Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy", <u>Cancer</u> , 83 (7), (October 1, 1998),1433-1439	
		AYALA, E , et al., "Effect of L-lysine monohydrochloride on cutaneous herpes simplex virus in the guinea pig", <u>Journal of Medical Virology</u> , 28(1), (May 1989),16-20	
		BASLOW, M. H., et al., "Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms", <u>Journal of Molecular Neuroscience</u> , 9(2), (October 1997),109-125	
		BINES, J. , et al., "Reducing parenteral requirement in children with short bowel syndrome: impact of an amino acid-based complete infant formula", <u>Journal of Pediatric Gastroenterology & Nutrition</u> , 26(2), (February 1998),123-128	
		CAO, Y , et al., "Effect of 7,12-dimethylbenz[a]anthracene (DMBA) on gut glutathione metabolism", <u>Journal of Surgical Research</u> , 100(1), (September 2001),135-140	
		CAO, Y. , et al., "Glutamine enhances gut glutathione production", <u>Jpen: Journal of Parenteral & Enteral Nutrition</u> , 22(4), (July-August 1998),224-227	
		CARDONA, P. , "Administration of glutamine and its dipeptides in parenteral nutrition. Which patients are candidates?", <u>Nutricion Hospitalaria</u> , 13(1), (January-February 1998),8-20	
		FAHR, M. , et al., "Vars Research Award. Glutamine enhances immunoregulation of tumor growth.", <u>Jpen: Journal of Parenteral & Enteral Nutrition</u> , 18(6), (November-December 1994),471-476	

EXAMINER

DATE CONSIDERED

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)



Complete if Known

Application Number	10/633,402
Filing Date	August 1, 2003
First Named Inventor	Klimberg, V. Suzanne
Group Art Unit	1614
Examiner Name	Weddington, Kevin

Sheet 2 of 3

Attorney Docket No: 781.020US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		FENG, ZULIANG, et al., "Glutamine prevents DMBA-induced breast cancer growth", <u>Surgical Forum</u> , 47(0), (1996),524-526	
		GUERRANT, R L., et al., "Cryptosporidiosis: an emerging, highly infectious threat", <u>Emerging Infectious Diseases</u> , 3(1), (January-March 1997),51-57	
		JUHL, J. H., et al., "Fibromyalgia and the serotonin pathway", <u>Alternative Medicine Review</u> , 3(5), (October 1998),367-375	
		KARINCH, A M., et al., "Glutamine metabolism in sepsis and infection", <u>Journal of Nutrition</u> , 131(9 Suppl), (September 2001),2535S-2577S	
		KLIMBERG, V S., et al., "Glutamine facilitates chemotherapy while reducing toxicity", <u>Jpen: Journal of Parenteral & Enteral Nutrition</u> , 16(6 Suppl), (November-December 1992),83S-87S	
		KLIMBERG, V S., et al., "Glutamine suppresses PGE2 synthesis and breast cancer growth", <u>Journal of Surgical Research</u> , 63(1), (June 1996),293-297	
		KLIMBERG, V S., et al., "Honorary Lectureship. Glutamine, cancer, and its therapy", <u>American Journal of Surgery</u> , 172(5), (November 1996),418-424	
		LABOW, B I., et al., "Glutamine", <u>World Journal of Surgery</u> , 24(12), (December 2000),1503-1513	
		MASTROIACOVO, P., et al., "Amino acids for dialysis patients", <u>Clinical Therapeutics</u> , 15(4), (July-August 1993),698-704	
		NEU, J., et al., "Enteral glutamine supplementation for very low birth weight infants decreases morbidity", <u>Journal of Pediatrics</u> , 131(5), (November 1997),691-699	
		OBRADOR, E., et al., "Glutamine potentiates TNF-alpha-induced tumor cytotoxicity", <u>Free Radical Biology & Medicine</u> , 31(5), (September 1, 2001),642-650	
		PICCIRILLO, N., et al., "Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis", <u>Haematologica</u> , 88(2), (February 2003),192-200	
		ROUSE, K., et al., "Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism", <u>Annals of Surgery</u> , 221(4), (April 1995),420-426	
		SKUBITZ, K M., et al., "Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study", <u>Journal of Laboratory & Clinical Medicine</u> , 127(2), (February 1996),223-228	
		TSAL, G., et al., "D-serine added to antipsychotics for the treatment of schizophrenia", <u>Biological Psychiatry</u> , 44(11), (December 1, 1998),1081-1089	
		WU, G., et al., "Dietary glutamine supplementation prevents jejunal atrophy in weaned pigs", <u>Journal of Nutrition</u> , 126(10), (October 1996),2578-2584	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/633,402
Filing Date	August 1, 2003
First Named Inventor	Klimberg, V. Suzanne
Group Art Unit	1614
Examiner Name	Weddington, Kevin

Sheet 3 of 3

Attorney Docket No: 781.020US1

		YAQOOB, P. , et al., "Cytokine production by human peripheral blood mononuclear cells: differential sensitivity to glutamine availability", <u>Cytokine</u> , 10(10), (October 1998), 790-794	
--	--	---	--

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached